Skip to main content
profile image
Selected Works of Shu-Ching Chang, PhD, MS
Presentation
Co‐expression of CD39 and CD103 identifies tumor‐reactive CD8 TIL in human solid tumors
Society for Immunotherapy of Cancer Annual Meeting (2017)
  • Thomas Duhen, AgonOx, Portland, OR, USA
  • Rebekka Duhen, AgonOx, Portland, OR, USA
  • Ryan Montler, AgonOx, Portland, OR, USA
  • Tarsem Mougdil, AgonOx, Portland, OR, USA
  • Bernard A Fox, AgonOx, Portland, OR, USA
  • Christopher Dubay, AgonOx, Portland, OR, USA
  • Shu-Ching Chang, Providence St. Joseph Health
  • Gary L. Grunkemeier, Providence St. Joseph Health
  • Jason McDermott, Pacific Northwest National Laboratory, Richland, WA, USA
  • Rom Leidner, AgonOx, Portland, OR, USA
  • Richard B. Bell, AgonOx, Portland, OR, USA
  • Andrew Weinberg, AgonOx, Portland, OR, USA
Abstract
Background
Identifying tumor antigen specific T cells from cancer patients has been a goal of tumor immunologists for several decades.

Methods
none

Results
Here we identified a subset of tumor‐infiltrating CD8 T cells (CD8 TIL) characterized by co‐expression of CD103 and CD39 in human solid tumors. This cell population was only found in TIL from primary and metastatic tumors, exhibited features of chronic stimulation and displayed characteristics of tissueresident memory T cells. Double positive CD8 TIL had a distinct TCR repertoire compared to other CD8 TIL subsets, were highly enriched for tumor antigen recognition and efficiently killed autologous tumor cells. Finally, patients with head and neck cancer whose CD8 TIL contained a higher frequency of CD39+CD103+ cells experienced a greater overall survival.

Conclusions
This work describes a simple method for detecting tumor‐reactive TIL, which should help define mechanisms of current immunotherapies and may lead to the development of future immunotherapies.
Disciplines
Publication Date
November, 2017
Location
National Harbor, MD, United States
Citation Information
Thomas Duhen, Rebekka Duhen, Ryan Montler, Tarsem Mougdil, et al.. "Co‐expression of CD39 and CD103 identifies tumor‐reactive CD8 TIL in human solid tumors" Society for Immunotherapy of Cancer Annual Meeting (2017)
Available at: http://works.bepress.com/shu-ching-chang/21/